Avalyn Pharma (NASDAQ:AVLN) Trading Down 5.3% – Here’s Why

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN) fell 5.3% during trading on Tuesday . The stock traded as low as $26.91 and last traded at $27.32. 118,307 shares were traded during mid-day trading, a decline of 67% from the average session volume of 357,884 shares. The stock had previously closed at $28.84.

Analysts Set New Price Targets

Several research firms recently commented on AVLN. Guggenheim began coverage on shares of Avalyn Pharma in a research report on Monday. They issued a “buy” rating and a $80.00 price target for the company. Morgan Stanley began coverage on shares of Avalyn Pharma in a research report on Tuesday. They issued an “overweight” rating and a $53.00 price target for the company. Wall Street Zen upgraded shares of Avalyn Pharma to a “hold” rating in a research report on Saturday, May 9th. Evercore began coverage on shares of Avalyn Pharma in a research report on Tuesday. They issued an “outperform” rating and a $51.00 price target for the company. Finally, Jefferies Financial Group began coverage on shares of Avalyn Pharma in a research report on Monday. They issued a “buy” rating and a $52.00 price target for the company. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $59.00.

Avalyn Pharma Stock Performance

Insider Buying and Selling at Avalyn Pharma

In related news, Director Jill Carroll purchased 277,778 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was purchased at an average cost of $18.00 per share, with a total value of $5,000,004.00. Following the completion of the acquisition, the director directly owned 2,186,562 shares in the company, valued at $39,358,116. This trade represents a 14.55% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of the business’s stock in a transaction on Friday, May 1st. The stock was acquired at an average price of $18.00 per share, with a total value of $9,999,990.00. Following the transaction, the insider directly owned 2,186,562 shares of the company’s stock, valued at $39,358,116. This represents a 34.06% increase in their position. The disclosure for this purchase is available in the SEC filing.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.